This study aims to determine the humoral response in HD patients, especially those who did not respond to the standard two-dose vaccination scheme, and to assess the increase in anti-S1-RBD IgG levels after the third dose of a SARS-CoV-2 mRNA vaccine. The gene discussed is PSMD1; the disease is Huntington disease.